Baseline Evaluation for Teriparatide Therapy
Before initiating teriparatide, measure serum calcium and ensure adequate vitamin D status; patients should receive 1000-1500 mg calcium and 400-1200 IU vitamin D daily supplementation, with serum calcium monitoring at 1 month after treatment initiation.
Essential Pre-Treatment Laboratory Assessment
Serum Calcium Measurement
- Baseline serum calcium is mandatory before starting teriparatide 1
- This establishes a reference point since transient hypercalcemia is a common side effect
- Patients with pre-existing hypercalcemia should not receive teriparatide
Calcium and Vitamin D Supplementation Requirements
The FDA label explicitly specifies supplementation requirements 1:
- Calcium: 1000-1500 mg daily (from combined dietary and supplement sources)
- Vitamin D: 400-1200 IU daily (minimum 400 IU, up to 1200 IU)
- These are not optional—all patients in clinical trials received this supplementation
Post-Initiation Monitoring
Serum Calcium Surveillance
Monitor serum calcium after 1 month of treatment 2. This timing is critical because:
- Hypercalcemia typically manifests within the first few months of therapy
- One measurement at 1 month is sufficient for most patients 2
- More frequent monitoring is unnecessary unless clinical concerns arise
Management of Hypercalcemia
If mild hypercalcemia develops 2:
- Reduce or withdraw dietary calcium supplements
- Consider reducing dosing frequency of teriparatide
- Most cases resolve with these conservative measures
A recent case report documented prolonged hypercalcemia (peak 11.78 mg/dL) after 3 months of therapy, which normalized one month after discontinuation 3. This underscores the importance of ongoing vigilance, particularly in underweight patients who may experience relative "overdosing" with standard 20 mcg dosing.
Bone Mineral Density Assessment
Baseline BMD Measurement
- Obtain baseline DEXA scan of lumbar spine and hip before treatment 4
- This establishes the starting point for monitoring treatment response
- The Endocrine Society guideline recommends repeat BMD measurement every 1-3 years during treatment 4
Expected BMD Changes
Understanding expected responses helps identify treatment failure 4, 1:
- Lumbar spine: 5.9-9.7% increase at 12-24 months
- Femoral neck: 1.5-2.8% increase at 12-24 months
- Total hip: 1.2-2.6% increase at 12-24 months
- Significant increases typically visible by 3 months
Additional Considerations
Contraindications to Screen For
While not explicitly detailed in the provided evidence, ensure patients do not have:
- Pre-existing hypercalcemia or hypercalcemic disorders
- Paget's disease of bone
- Prior skeletal radiation
- Bone metastases or skeletal malignancies
Special Populations
Underweight patients may require closer calcium monitoring due to potential relative overdosing with standard 20 mcg daily dosing 3. Consider more frequent calcium checks in patients with BMI <18.5 kg/m².
Duration Limitations
Teriparatide should not be used for more than 2 years based on osteosarcoma findings in rat toxicology studies 2, 5. This is a critical safety consideration that should be discussed with patients before initiation.
Common Pitfalls to Avoid
Excessive calcium supplementation: Total daily calcium intake should not exceed 1500 mg 2. Higher doses may increase hypercalcemia risk.
Inadequate vitamin D: Ensure vitamin D sufficiency before starting therapy to optimize calcium homeostasis.
Concurrent bisphosphonate use: Avoid concurrent antiresorptive therapy, particularly bisphosphonates, as this may blunt teriparatide's anabolic effects 2.
Inadequate monitoring: While extensive monitoring is not required, the 1-month calcium check should not be omitted 2.